Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-18 · accession 0001610717-25-000021 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-19 | 2025-02-18 | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $19.52 | +12.8K | 690.7K | +2% | +$250.0K |
| D | 2025-02-19 | 2025-02-18 | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $0.00 | -12.8K | 182.2K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-18 | M | A | 12,808 | $19.52 | 690,695 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2025-02-18 | M | D | 12,808 | $0.00 | 182,192 | D | $19.52 · — to 2031-02-23 | 12,808 Common Stock | (F1) The shares subject to the option are fully vested and exercisable. |